Funding sources None.
An exploration of reported mortality from cutaneous squamous cell carcinoma using death certification and cancer registry data
Article first published online: 30 AUG 2013
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 3, pages 682–686, September 2013
How to Cite
Rose, R.F., Boon, A., Forman, D., Merchant, W., Bishop, R. and Newton-Bishop, J.A. (2013), An exploration of reported mortality from cutaneous squamous cell carcinoma using death certification and cancer registry data. British Journal of Dermatology, 169: 682–686. doi: 10.1111/bjd.12388
Conflicts of interest None declared.
- Issue published online: 30 AUG 2013
- Article first published online: 30 AUG 2013
- Accepted manuscript online: 21 APR 2013 10:15PM EST
- Manuscript Accepted: 9 APR 2013
Cutaneous squamous cell carcinoma (cSCC) is increasing in incidence but mortality rates are low. Identifying high-risk tumours is important when rationalizing clinical review for patients with cSCC.
To assess the accuracy of death certification in cases of reported fatal cSCC and to identify risk factors for fatal cSCC.
A retrospective, observational study of cases of fatal cSCC over 11 years (1993–2004) in Leeds, identified in cancer registry and death certification data.
Fifty-eight patients were recorded by the registry as having fatal cSCC in this period. Review of case notes and pathology specimens, where available (34 cases), confirmed that 21/34 patients had died of cSCC. Five were on the ear and none on the lip. Four patients had been treated for leukaemia or lymphoma and one was a renal transplant recipient. On pathology review five patients proved to have had malignant adnexal tumours rather than cSCC, and one a melanoma. In addition, three patients had disease of the ear canal or vulva.
A proportion of deaths were falsely attributed to cSCC as a result of inaccurate histological diagnosis. Some fatalities were related to tumours in sites known to be at higher risk, and a significant proportion was postulated to be related to immunosuppression. In those cases attributed to cSCC in which this could be assessed, the majority were American Joint Committee on Cancer stage 2 and only 24% were in high-risk sites.